| Inhibition of human CYP2C9 at 1 uM - BioAssay Summary N-Myristoyltransferase (NMT) represents a promising drug target for human African trypanosomiasis (HAT), which is caused by the parasitic protozoa Trypanosoma brucei. We report the optimization of a high throughput screening hit (1) to give a lead molecule DDD85646 (63), which has potent activity against the enzyme (IC(50) = 2 nM) and T. brucei (EC(50) = 2 nM) in culture. The compound has good more .. |
_ | |
||||||||||||||||||||||||||||||||||||||||||||||||
Target Tested Compound: Description: Title: Discovery of a novel class of orally active trypanocidal N-myristoyltransferase inhibitors. Abstract: N-Myristoyltransferase (NMT) represents a promising drug target for human African trypanosomiasis (HAT), which is caused by the parasitic protozoa Trypanosoma brucei. We report the optimization of a high throughput screening hit (1) to give a lead molecule DDD85646 (63), which has potent activity against the enzyme (IC(50) = 2 nM) and T. brucei (EC(50) = 2 nM) in culture. The compound has good oral pharmacokinetics and cures rodent models of peripheral HAT infection. This compound provides an excellent tool for validation of T. brucei NMT as a drug target for HAT as well as a valuable lead for further optimization. (PMID: 22148754) Categorized Comment ChEMBL Assay Type: ADMET ChEMBL Assay Data Source: Scientific Literature ChEMBL Target ID: 12911 ChEMBL target type: Target is a single protein chain Result Definitions
Data Table (Concise) Classification
PageFrom: |
||||||||||||||||||||||||||||||||||||||||||||||||||